COVID-19
The company is working to build a global consortium of pharma and chemical manufacturers in order to expand global capacity and production. They are also working with regulators on emergency use authorizations for the drug.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.
As the situation progresses, they hope to establish more production suites across Lonza’s facilities globally, with a goal of manufacturing up to 1 billion doses of mRNA-1273 per year at the currently expected dose of 50 µg.
A vaccine for COVID-19 is unlikely to be ready in 2020, according to biopharma professionals responding to the BioSpace Workplace Survey: The Impact of COVID-19 – Spring 2020. Only 25% of respondents thought a vaccine might be possible this year.
The COVID-19 pandemic has increased the pace of drug development and regulatory approval dramatically, accelerating activities in ways that shorten the time needed to deliver safe, effective therapeutics, vaccines and diagnostics to patients.
BioSpace spoke to Aurika Savickaite, RN, MSN, to learn more about the ventilator helmet initiative, NIV helmets, and how they can be used during this coronavirus pandemic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 30, 2020.
“Although a 31% improvement doesn’t seem like a knockout 100%, it is a very important proof of concept,” said Anthony S. Fauci, director of NIAID. “What it has proven is that a drug can block this virus. This will be the standard of care.”
Recent reports revealed that the infection rates between adults and children were similar, but men are more likely to exhibit severe symptoms. The report also highlights the importance of contact tracing to help mitigate infection rates.
Gilead announced topline results from the open-label, Phase III SIMPLE trial looking at 5-day and 10-day dosing of the drug in hospitalized patients with severe disease. It also reported positive data from the National Institute of Allergy and Infectious Diseases’ trial of the drug in COVID-19.
PRESS RELEASES